Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed May 11, 2026 · 10-Q · 41 days after period end · 0001104659-26-058631
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$1.68M | -$2.15M | -$4.38M | -$2.90M |
| EPS Diluted | -$0.62 | -$2.15 | -$0.28 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 11, 2026 · 41 d after period end
